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INTRODUCTION
Advancements in genetics research are rapidly transforming the fields of personalized
medicine and population research. These developments will introduce a wide range of difficult
bioethical issues and raise many yet unaddressed legal concerns. On September 5, 2012, Nature,
Cell, Science, Genome Research, and other scientific journals released a coordinated publication
of thirty articles detailing the groundbreaking findings of The Encyclopedia of DNA Elements
(ENCODE) consortium.1 The ENCODE consortium represents new research that for the first
time confirms that over eighty percent of our DNA which was once thought of as “junk” with no
function actually plays a “critical role in controlling how cells, tissue, and organs behave.”2
These portions of the genome, once disregarded as non-protein-coding DNA (ncDNA) are now
being described as genetic “switches” that may lead to many discoveries about disease.3
Imagine a patient walking into his physician’s office, handing the physician a memory
stick and saying: “Here, look at all 3.2 billion base pairs of my DNA and tell me exactly what is
wrong with my cancer and how you are going to treat it.” According to Dr. George Sledge Jr., a
past president of the American Society of Clinical Oncology, this scenario could become a
reality in as few as two to three years.4 Advancements in the field of genetic testing will change
clinical practices and patient expectations, which will shift boundaries of medical malpractice
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law, expand the meaning of informed consent, and present new challenges in bioethics and
privacy.
Although there is much to be gained from learning more about individual genomes,
genetic information can reveal highly sensitive personal information such as medical history,
familial relationships, predisposition for disease, and possibly even behavioral tendencies.5 The
government has already recognized the potential gains from genetic testing, as well as the
concerns that individuals might have about the confidentiality of their genetic information.6 The
Genetic Information Nondiscrimination Act was enacted to address these concerns and promote
genetic testing.7 It is likely that GINA and other protective privacy measures will encourage
more individuals to undergo genetic testing.
As more about the human genome is revealed and more patients choose to undergo
genetic testing, it is increasingly important to develop professional guidelines and
recommendations that take into account new genetic discoveries and testing techniques. In order
to provide an argument in support of the further development of professional guidelines, this
paper will consist of four sections. Section I will discuss the background of genetic testing, the
Human Genome Project and the ENCODE Consortium. Section II will explore the legal issues
surrounding genetic testing and discuss the implications that increased genetic testing will have
on the doctrines of medical malpractice and informed consent. This section will also discuss how
the law will be challenged by rapidly developing advancements such as the ability to detect
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genetic “switches.” Section III will examine the unique legal and bioethical concerns that arise
from the interplay between patient privacy and the duty to warn third parties of genetic diseases.
Finally, Section IV will conclude that in order to promote the advancement of personalized
medicine, it will be important to increase genetics education and establish professional
guidelines that recognize advancements made in whole genome sequencing while preserving
patient confidentiality.
I. ENCODE: THE NEW FRONTIER OF GENETIC TESTING
Technological innovation has made genetic testing more accessible and an increasing
number of individuals now have the opportunity to access and interpret their own genetic
information.8 The price of sequencing an entire human genome is dropping rapidly and it may
soon cost a consumer only $1,000 for an entire genetic blueprint.9 This genetic blueprint can
reveal predispositions to cancer, diabetes, and even psychiatric conditions.10 The cost of
sequencing the entire genome, consisting of more than 20,000 genes and 6 billion DNA building
blocks, will soon be less than that to perform individual tests for cancer or metabolic disease.11
Whole genome sequencing has already made promising developments in the field of
targeted gene therapy.12 In 2009, the Memorial Sloan Kettering Cancer Center conducted a phase
II trial of the kidney cancer drug Everolimus on patients with bladder cancer.13 Although the trial
was unsuccessful overall, one patient (Patient X) responded remarkably well to the drug and
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went into complete remission.14 The researchers then used array-based tools to perform a
targeted search of the Patient X’s tumor DNA for mutations and variations.15 When that did not
produce significant results, they sequenced the tumor’s entire genome to detect potential
biomarkers.16 This whole genome sequencing revealed that there were indeed two mutations
unique to Patient X.17 Upon referencing previous studies, scientists discovered that one of these
mutations had been shown to sensitize patients to the same protein that is targeted by Everolimus,
likely deducing the source of Patient X’s positive response.18 Scientists believe that experiments
in this vein can continue to identify previously undetected subtypes of disease that can then be
targeted and treated through personalized therapies.19
Whole genome sequencing will likely increasingly be used as a discovery platform.20
Namely, the federal government spent $288 million to support development of the Encyclopedia
of DNA Elements (ENCODE), an international research collaboration that follows up on and
supplements the Human Genome Project (HGP).21 The goal of the HGP, an international,
collaborative research program jointly managed by the U.S. Department of Energy and the
National Institutes of Health, was to map and sequence the genes of the human body.22 In 2003,
the HGP was successfully completed.23 ENCODE now aims to provide a deeper understanding
of the “functional” elements of the genome and serve as a catalog of these segments.24
14
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One of ENCODE’s most ground-breaking discoveries is that certain non-protein coding
regions serve much larger functions than previously thought.25 So far, four million switches,
also called transcription factors or “regulatory genes,” have been discovered.26 Study results
found that regulatory genes are responsible for common diseases such as Crohn’s disease and
about 17 major different types of cancer. 27 Gaining understanding of these networks of genetic
switches may prove to provide new targets for drug therapy and greatly expand personalized
medicine.28 Namely, genome-based research will eventually allow scientists to develop highly
effective diagnostic tests to better understand the health needs of people based on their unique
genetic make-ups, and to design personalized treatments for diseases.29
Laboratories and clinicians will benefit from collaborating to understand the relationships
between sequence variations and health conditions within the context of ENCODE’s findings.
Clinical decisionmakers will be also need to take these findings into account in order to avoid
inappropriate recommendations that may cause patient harm.30 As data on current practices on
genetics reporting and its impact on health outcomes continues to accumulate, it will be
important to survey these practices and how they link to patient outcomes. These new
discoveries will reshape the boundaries of medicine and should be taken into account when
addressing legal and bioethical quandaries that will inevitably arise as genetic testing becomes
more prevalent.
II. THE CHANGING LANDSCAPE OF LIABILITY
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The possibility of linking DNA variations with health conditions will result in
unprecedented ways to predict and treat diseases.31 In a pilot study Mike Snyder, the head of the
Center for Genomics and Personalized Medicine and Stanford University, decided to sequence
his own genome in order to demonstrate the capabilities of personal genomics.32 Snyder
explained that he wanted to sequence his DNA to see if it would predict conditions that he might
be at risk for, particularly those that were not evident from his family history. 33 The sequencing
revealed that the seemingly healthy Snyder was at high risk for type 2 diabetes.34 Snyder stated
that he believed that the early detection would allow him to manage the risk through diet and
increased exercise, thereby mitigating an otherwise debilitating disease.35
Although advancements in whole genome research will play a role in making medicine
more preventative, personalized and effective, there are significant gaps in the U.S. system of
genetic testing oversight that can lead to harms.36 Further, customs in the genomics industry are
not yet fully developed.37 As genetic testing continues to grow exponentially, the number of
qualified clinical geneticists and genetic counselors is unlikely to meet the demand, and an
increasing amount of general physicians may be expected to offer, interpret and convey genetic
tests results.38 Thus, increased validation and acceptance of genetic testing in clinical practice
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could result in a challenging time for physicians.39 Physicians will be at the forefront of genetics
medicine and may be faced with changing forms of liability for medical malpractice, lack of
informed consent, and the legal duty to warn.
1. Medical Malpractice: Standard of Care
As physicians incorporate genetic services into their practice, the framework for
analyzing medical malpractice cases will change. Medical malpractice claims are based on
negligence40 and must include a duty owed by the physician to his patient, a breach of that duty,
causation, and damages.41 The physician-patient duty is unique in that it is upheld if the
physician meets the required standard of care.42 Generally, the standard of care is measured by
the level of care demonstrated by other physicians in the same field in terms of skill, knowledge
and care.43
Genetics knowledge, skills, and abilities vary greatly across the discipline, making it
difficult to make standard of care determinations. In a survey of six allied healthcare training
programs, 78 percent of graduates reported that they received marginal to no instruction on
genetics knowledge and skills.44 However, even though they had minimal levels of genetics
education, these professionals were still responsible for providing clinical services relevant to
genetics, such as taking family genetic histories and counseling patients on the genetic basis for
the disorders.45 As the personal genomics industry grows, it will be important for primary care
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providers to equip themselves with the necessary knowledge and skills to assess patients’
situations. The wide range of genetics care providers, ranging from geneticists who have medical
degrees to laboratory technicians, implies that some types of providers may be more qualified
than others depending on the nature of the test and the complexity of the condition at issue.46
Currently, the American Medical Association (AMA) predicts that only ten percent of
physicians possess the requisite knowledge to use genetic testing.47 Due to the low percentage of
general physicians who genetic testing services, it may be difficult to establish a standard of care
that would give rise to liability for failure to administer genetic testing services.48 However, as
more genetic tests for common chronic disorders become incorporated into primary practice,
even health care professionals who do not have specialized training in genetics may be held to
the same standard of care as clinical geneticists. This may impose general practitioners with a
heightened standard of care and resulting malpractice cases that they are not prepared to prevent.
This issue is compounded by the fact that patients may be more confident in their primary
physicians’ ability to convey genetic services than statistics should currently suggest.49 The
AMA reported in a survey that over 60 percent of respondents would choose their primary care
doctor as their first consultant on genetic disorders.50 In addition, about 80 percent reported
feeling “very confident” or “somewhat confident” that their primary care provider could advise
them or their family members about risk for developing inherited cancer, counsel them about
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available genetic tests, and interpret results from the test.51 However, a separate study conducted
by the National Cancer Institute concluded that only 40 percent of primary care physicians and
57 percent of tertiary care physicians felt that they were qualified to recommend genetic testing
for cancer susceptibility to their patients.52
Studies have shown that the level of genetics knowledge of the primary care provider
greatly determines willingness to offer genetic testing and services.53 Attitudes and acceptance of
testing are also dependent on complex balancing tests of the benefits, risks, and costs of genetic
testing.54 Notably, providers will be faced with the challenge of constantly maintaining
knowledge of what tests are currently available, and how accurate and valid the tests are.55 The
burden of attaining rapidly changing knowledge about genetics, including new findings that
come from ENCODE, may prove to be a deterrent for providers who do not wish to incur
liability for care related to genetic services.56
Further, even if a physician purports not to offer genetics services, plaintiffs may still
succeed in bringing a case under the current standard of care. According to the Restatement
(Second) of Torts, “[i]n determining whether conduct is negligent, the customs of the community,
or of others under like circumstances, are factors to be taken into account, but are not controlling
where a reasonable man [or woman] would follow them.”57 For example, if there is sufficient
knowledge in the medical community that a certain set of gene mutations cause a particular
51
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disease to develop, and the physician does not follow up with a patient whose medical records
show these gene mutations which in turn lead to that patient’s injuries, the physician could face
liability under this standard.58 The physician may argue that due to his limited background in
genetics related care, medical custom would not dictate him to follow up with his patient
regarding the predicted disease.59
However, if a reasonable person, given the prominence of the predictive test, would have
conducted follow up care, medical custom may not prescribe the outcome.60 This reasonable
person objective standard has been applied by at least one court in a medical malpractice
setting.61 In Helling v. Carey, the court stated that although an early glaucoma detection
technique using air puffs tests was not in routine use by ophthalmologists, the court could impose
liability for breaching the standard of care.62 The court stated that “irrespective of its disregard
by the standards of the ophthalmology profession, it is the duty of the courts to say what is
required to protect patients.”63 Under this same reasoning, the lifesaving potential of genetic
testing and follow up care could lead courts to impose liability for physicians who fail to utilize
available testing and care.
Physicians who do choose to offer genetic testing services will be exposed to even more
forms of liability. For example, they could be held liable for an incorrect interpretation of test
results and for recommending a suitable course of treatment or drug therapy. Further, physicians
will have to consider the fact that simply revealing genetic information to patients could have
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unexpected effects on the patients’ psyche.64 To prevent these situations, it will be crucial for
physicians to establish obtain informed consent with patients before engaging in genetics
services.
2. Lack of Informed Consent as Liability
The theory of informed consent raises significant areas of liability for physicians. The
need for informed consent is based in the principles of autonomy and self-determination and
recognizes the patient’s desire to decide which tests and procedures to undergo.65 In order to
establish informed consent liability, an injured patient must show that his physician failed to
disclose all information pertinent to the test or procedure, including benefits, risks, and
alternatives.66 The patient must also establish by a preponderance of evidence that if the patient
had received all of the pertinent information, he would have chosen an alternative means of
treatment.67 As applied to genetic testing, the injured patient might allege that, if given all the
relevant information about undergoing a certain treatment plan, the patient would have asked for
a genetic test to determine whether he would be negatively impacted by the treatment, and would
have either avoided the treatment altogether or undertaken a alternative means of treatment.68
Similar to other medical malpractice claims, claims for lack of informed consent may be
evaluated under the “reasonable practitioner” standard, which states that the plaintiff must
establish what a reasonable physician would disclose to his patient, prove that his own physician
failed to disclose than information, and then show that he was harmed by this lack of
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disclosure.69 This standard, which has been relatively easy to meet due to the limited practice of
genetic testing, may shift as genetic testing becomes more widespread.70 Further, some states
hold physicians to an informed consent standard according to what a “reasonable patient” would
need to know to make an informed decision.71 This patient-centered approach dictates that “the
test for determining whether a particular peril must be divulged is its materiality to the patient's
decision,” and that “all risks potentially affecting the decision must be unmasked.”72 Under this
standard, patients who bring a cause of action for a physician’s failure to provide a genetic test
would be required to show that a test was commercially available that would provide results that
would dictate the patient’s course of action.73 However, if there was no test commercially
available, then the information would not be considered materially relevant.74 Advancements in
genetic testing techniques such as the ENCODE findings will increase the number, power, and
accuracy of genetic tests, necessitating clear informed consent and communication between
physicians and patients.75
As findings from ENCODE and similar whole genome sequencing projects begin to
disseminate throughout the medical community, physicians may increasingly be held liable for
failure to provide genetic tests or failure to properly interpret those tests.76 In order to avoid
liability, doctors may find it necessary to learn about these techniques and incorporate them in to
their practice.77 Finally, physicians who do engage in genetic testing services will be faced with a

69

Id.
Id.
71
Heinemann, supra note 65.
72
Canterbury v. Spence, 464 F.2d 772, 786-87 (D.C. Cir. 1972) (citing Jon R. Waltz & Thomas W.
Scheuneman, Informed Consent to Therapy, 64NW. U. L. REV., 628, 639-41 (1970).
73
Donovan, supra note 39.
74
Id.
75
Id.
76
Id.
77
Id.
70

12

challenging legal and bioethical issue that pushes the boundaries of confidentiality and the
physician-patient relationship: the duty to warn.

III. THE DUTY TO WARN: INCREASING TENSION BETWEEN PATIENT CONFIDENTIALITY AND
AVERTING HARM
1. Legal Duty to Warn
Genetic testing presents the unique problem of not only identifying the risk for disease
for patients but also for family members who may not be receiving care from the physician
providing the test.78 Most medical professional organizations take the policy position that
physicians should actively encourage patients with inherited diseases to inform their at-risk
family members.79 Certain hereditary diseases, such as breast cancer, have mutations that can be
easily detected. Predictive tests, or susceptibility tests, include those for breast and ovarian
cancer, colon cancer, and Alzheimer’s disease.80 In the case of breast cancer, mutations in
BRCA1 and BRCA2 are highly associated with increased risk for both breast and ovarian
cancer.81 Patients who test positive for mutations may elect for cancer prophylaxis or even take
preventative measures such as mastectomies.82 However, patients who choose to take preventive
measures for themselves may not want to reveal this sensitive information to family members.83
Depending on the jurisdiction, the hereditary nature of genetic traits creates a unique
situation for physicians who offer genetic testing to their patients but do not share test results
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with the patients’ close relatives. For instance, in Florida84 and New Jersey,85 physicians have the
duty to inform patients that they should warn close relatives if genetic testing reveals harmful
genotypes.86 New Jersey courts have gone even further to say that warning the patient may not
be enough, indicating that physicians may be required to give patients’ relatives direct warnings
with whom they may have no physician-patient relationship.87
The physicians’ legal duty to warn was established in Tarasoff v. Regents of the
University of California.88 In Tarasoff, a woman was murdered by a man who was obsessed with
her after he had shared his intention to kill her with his psychotherapist.89 The court held that a
physician has a duty to warn if 1) he has a special relationship with either the person who may
cause harm or the potential victim, 2) the person at risk is identifiable, and 3) the harm is
foreseeable and serious.90 The Tarasoff duty to warn identifiable individuals at risk of harm is
significant for physicians in the context of genetic testing because genetic test results may
identify potential risk of harm for patients’ relatives.91 Particularly, case law has suggested that
physicians may have a duty to disclose genetic information to families of patients when related
individuals may need it to make informed reproductive choices92 or when they are genetically
susceptible to potentially harmful genetic traits demonstrated in the physician’s patient.93
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For example, In Pate v. Threkel,94 Heidi Pate, the adult daughter of a woman who had
thyroid carcinoma, a genetically inheritable disease, sued her mother’s physician for medical
malpractice after she developed the same disease three years after her mother’s treatment was
completed.95 Her complaint stated that her mother’s physician knew or should have known that
the disease was hereditary and that the physician had a duty to warn her mother that her that her
children should be tested for the disease.96 Further, she alleged that if her mother had been
warned, she would have had her children tested, and that if Pate had been tested at that time, she
would have taken preventive action and could have cured her condition.97
The Florida court ruled that the physician did have a duty to warn Pate’s mother due to
the genetically transferable nature of her disease,98 and that this duty should run to the “intended
beneficiary of the prevailing standard of care.” 99 As the patient’s child, the court said, Pate was
an intended beneficiary of her mother’s care, and the lack of a direct physician-patient
relationship did not “foreclose liability if a duty of care [was] otherwise established.”100 Thus, in
cases in which the prevailing standard of care creates a duty that is intended to benefit
identifiable third parties, then the physician's duty extends to those third parties.101 However, the
court was careful to note that the physician was not required to personally warn the patient's
children.102 They duty would be satisfied “in any circumstances in which the physician has a
duty to warn of a genetically transferable disease,” by warning the patient.”103
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In a similar New Jersey case, Safer v. Estate of Pack, a patient diagnosed with a
hereditary form of colon cancer brought a malpractice claim against the estate of the physician
who had treated her father thirty-four years earlier, alleging that the doctor had breached his duty
to warn her that she was at risk of developing the hereditary disease.104 Although there was no
direct physician-patient relationship, the court stated that a doctor had a duty to warn those
“known to be at risk of avoidable harm from a genetically transmissible condition,”105and
postured that there was no “essential difference” between protecting third parties from
contagious disease or physical harm and protecting them from potential genetic disease.106 In
certain situations, “[t]he individual or group at risk is easily identified, and substantial future
harm may be averted or minimized by a timely and effective warning.”107 Notably, unlike
the Pate court, the Safer court did not assert that a physician satisfies his duty to warn
of avoidable risks by informing only the patient of the disease’s hereditary nature.108 Rather, the
court stated that duty to warn can be discharged, especially with respect to at-risk children, if
reasonable steps are taken to assure those most likely to be affected are given the proper
information.109 Finally, while the court recognized that there was a potential conflict between its
stated duty to warn and physician-patient confidentiality, it elected not to resolve that issue.110
2. Ethical Duty to Warn- The Importance of Maintaining Patient Confidentiality
The tension between physicians’ duty to warn third parties of genetic disease through
familial risk and the duty to respect their patients’ confidentiality is a difficult conflict with
ethical implications. Genetic test results may impact individuals and their families with
104
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implications for obtaining insurance and employment and affect decisions pertaining to
childbearing, diet, and physical activities.111 Specifically, “genetic predestination” is a theory
that may significantly alter the lives of those who learn the results of their genetic tests.112 As
genetic testing becomes more common and whole genome sequencing is able to reveal more
accurate results about an individual’s health, physicians need maintain their primary obligations
of promoting the best interests of their patients.113 However, physicians should also make best
efforts to cooperate with the patient in informing at-risk family members or obtain consent to
inform them.114
According to the National Human Genome Research Institute (NHGRI), due to the
complexity of the decision about whether to be tested for genetic disease, it is recommended that
those considering undergoing testing first consult with genetic counselors who are trained to
“help individuals and families weigh the scientific, emotional, and ethical considerations” that
may impact their decision.115 In fact, as the amount of genetic information resulting from the
HGP and ENCODE increases, physicians may soon have the professional responsibility to
ensure that their patients receive genetic counseling in appropriate cases.116 Physicians who offer
genetics services may be expected to assess the risk of a genetic disorder by researching and
evaluating family history and medical records, interpreting the results of genetic tests and
medical data, and explaining possible treatments, preventive measures, and reproductive
options.117 In addition, they may need to weigh the medical, social, and ethical decisions
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surrounding genetic testing, provide support and information relevant to the decision, counsel or
refer individuals and their families to support services, and serve as patient advocates.118 As
physicians who perform genetic tests are faced with rising standards of care, they must carefully
consider their ethical obligations to their patients, patients’ families, and society as a whole.
Significant bioethical concerns, such as the duty to preserve confidentiality of medical
information, will emerge as genetic testing becomes more predictive. This duty, which is rooted
in respect for the patient’s autonomy, dictates that physicians must maintain the confidentiality
of their patients’ genetic information and abide by best-practices to avoid potentially
unauthorized or inappropriate disclosure of patients’ genetic data.119 Patients may not want to
share results with family members for fear of backlash or concern, and this should be taken into
account even when potential of risk to family members is high.
The duty to warn, which is based the principles of beneficence and nonmaleficence,
supports the disclosure of relevant genetic information to family members who might be
affected.120 The principle of justice recommends that family members have the right to the same
access to testing and options to reduce risk as patients who receive tests.121 Disclosure of genetic
test results may greatly benefit family members by giving them necessary access to surveillance
and preventative therapies that could reduce the risk of developing the disease.122 Nondisclosure
may actually harm at-risk relatives who might develop the familial condition without their
knowledge.123 In addition, delayed diagnosis could limit treatment options and curability.
Professional associations, such as the AMA, have recognized that while physicians must protect
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the confidentiality of patient disclosures and information, “countervailing societal interests” may
justify the breach of confidentiality.124 Disclosure may be justified particularly when the at-risk
relative is identifiable, the genetic disorder is highly likely to be present, the disorder is treatable
or preventable, and medically accepted standards indicate that early monitoring will reduce the
genetic risk.125 Under all circumstances, the harm that would result from failure to disclose
should outweigh the harm that may result from the disclosure.126
The reasons for this ethical position are significant. First, the physicians’ duty to protect
patient confidentiality, especially with respect to highly sensitive health conditions, is stronger
than the duty to warn family members with whom no physician-patient relationship has been
established.127 Although third parties may stand to benefit from being informed of their relatives’
genetic test results, the development of whole genome sequencing and increased genetic testing
supports an emphasis on respect for patient autonomy. Namely, disclosure to third parties
without the patient’s consent should only be recommended in exceptional situations where it is
the last resort.128 As genetic testing becomes more common among the patient population, it is
less likely that relatives will be harmed by the failure of their relatives’ physician to warn them
of possible risk, making it less crucial for that physician to extend the duty to warn.
Ideally, individuals should be able to have complete control their genetic information and
its dissemination. To this end, physicians should strive to work with patients to obtain informed
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consent and to cooperate in the responsible disclosure of test results to family members. Thus, it
will be crucial to thoroughly counsel patients about the possible consequences of genetic testing,
its limitations, implications for family members, and the right to protect the confidentiality of the
information prior to undergoing genetic testing. The patient’s response to pre-test counseling and
willingness to include family members in the testing progress should alert health care providers
to potential communication problems within the patient’s family.
On the other hand, decisions to disclose to at-risk family members must also consider
respect for the autonomy of those family members and the “right not to know” about a relative’s
genetic information.129 There are a number of potentially negative implications from sharing
genetic test results with at-risk relatives. In addition to possible discrimination, the disclosure
that one is genetically predisposed to or a carrier for a disease may cause devastating
psychological and emotional damage.130 This may be particularly true for condition such as
Huntington’s disease, when there is no cure for the disease and its onset is a virtual certainty.131
Testing may also cause familial division if some members protest the test itself because they do
not want to open an investigation into the family’s genetic reality.132 For these reasons, health
care providers should not inform at-risk relatives of a patient’s genetic test results without first
determining whether the relative would like to learn the information.133 However, an exception
may be made when the patient is a minor and the potentially at-risk relatives are the child’s
biological parents, because the parents may need this information to make informed decisions
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about their child’s medical care and it may help parents make informed reproductive
decisions.134
Finally, when considering the duty to warn, physicians must assess the accuracy of the
genetic test in question and avoid using tests that have not been evaluated for safety and
effectiveness. Even if the genetic test generally provides accurate results for single-gene
disorders, it might have significantly weaker predictive power for multifactorial disorders.135
Heart disease, diabetes, most cancers, and Alzheimer's disease are examples of multifactorial
disorders whose mutations often do not guarantee the onset of disease because they result from
the interaction of multiple genes and environmental factors.136 The discoveries from ENCODE,
and further knowledge about genetic switches, will likely shed light on the development of
multifactorial disorders and hopefully increase the accuracy of predictive tests. Increasing
accuracy may be able to provide at-risk relatives with clinically relevant information and enable
them to take meaningful action to avoid future harm.
The increase in the amount of genetic information available has led to the call for, and
adoption of, new legislation on both state and federal levels to protect the confidentiality of
genetic information and prevent discrimination based on genetic information in employment and
health insurance contexts.137 However, there is no legislation that specifically speaks to the duty
of health care providers to disclose genetic information about their patients to the relatives of

134

Denbo, supra note 129 at 597.
NHGRI, supra note 22.
136
Id.
137
Forty-one states have enacted laws regulating genetic discrimination in health insurance and thirty-one
states have enacted legislation addressing genetic discrimination in the workplace. For a searchable
database of the federal and state laws pertaining to “privacy of genetic information/confidentiality;
informed consent; insurance and employment discrimination; genetic testing and counseling; and
commercialization and patenting,” see NHGRI, Policy and Legis. Database,
www.genome.gov/PolicyEthics/LegDatabase/pubsearch.cfm.
135

21

those patients.138 There is a need to enact a consistent floor of privacy protections covering
whole genome sequence data and to prohibit unauthorized whole genome sequencing without
full informed consent. In addition to preserving patient privacy and confidentiality, many other
steps need to be taken in order to ensure that the medical field is able to progress by allowing
genetic testing and whole genome sequencing to fully advance. Until legislatures establish clear
guidelines regarding a physician’s duty to warn relatives of their possible genetic risk, physicians
may benefit from increased education and the creation of policies and guidelines in a
professional code of conduct that recognizes current advancements in genetics medicine.
IV. RECOMMENDATIONS: INCREASED EDUCATION AND UNIFORM STANDARDS
Newly emerging genetic discoveries and testing techniques such as whole genome
sequencing are likely to be accompanied by an onslaught of litigation previously unseen by
physicians and courts. Presently, the majority of physicians is not adequately trained and
educated about advancements in genetic research and may be unaware of legal consequences.
Currently, no state or federal laws exist to address whole genome sequence data
comprehensively, while specific laws designed to protect genetic information in general typically
address where the data is collected and by whom, but may or may not offer protection. 139In
order to assist the medical community to adopt these valuable new resources, as well as to
provide courts with a suggested standard of care, it will be important to incentivize increased
genetics education and a set of uniform medical practice guidelines.
1. Increased Education
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In order to adapt to the changing field of medicine and for patients to benefit from
scientific advancements, physicians will need to become better educated and trained in the field
of genetic testing. Currently, primary care physicians are not adequately prepared to assume
responsibility for their patients' genetic services. For example, in a survey of 124 primary care
physicians, twenty percent were unaware that a predisposition to breast cancer could be
determined by a genetic test.140 Another survey about primary care physicians' knowledge about
genetic testing for colon cancer found that the physicians' incorrect interpretation of the test
results would have led them to provide their patients with inaccurate information in 31.6% of the
cases.141 These studies demonstrate what may happen as genetic tests become available for
public use before physicians are properly trained in when and how to use them. If physicians
have the duty to disclose genetic information to their patients, they will either have to undertake
the testing themselves or refer to experts who can.142 Thus, it is clear that physicians need to
become more familiar with the capabilities of genetic testing to advise their patients or risks or to
refer them for genetics services.
In order to assure that physicians receive adequate education and training, it will be
crucial for more genetics teaching to be included in medical schools, residency programs, and
medical board exams. It may be beneficial for physicians to obtain certifications to require
demonstration of sufficient knowledge in genetics prior to providing genetically based health
care. Hospitals and health management organizations should require competence in the field of
genetics a prerequisite to allowing them to provide genetic counseling or testing. Particularly in
the context of managed care systems, primary care physicians occupy roles as the “gatekeepers”
140
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of their patients' medical care and may be increasingly called on to interpret genetic test results
for their patients.143 Moreover, as science reveals more about the origins of multifactorial
disorders, the number of individuals potentially at risk for the development of these disorders
will increase, and initial genetic risk assessments may become an expected standard in primary
care medicine.144 Thus, there must be increased efforts to promote health professional education
and access to information about advancements in genetics medicine. Although transitioning into
this new realm will be challenging, new methods of genetic testing through early detection,
prevention, and treatment, will benefit doctors, patients, and the health care of the nation.
2. Professional Guidelines
As new advancements in genetics are made, medical and legal communities must
recognize their responsibilities to inform themselves of current developments and to create
appropriate standards so that patients receive quality care. This may be accomplished by the
creation of a regularly updated set of professional guidelines that may be used to guide
enforcement to maintain the integrity of genetic testing. These guidelines should survey the
current state of how physicians are using genetic testing in clinical practice and provide
anticipatory recommendations on how to incorporate new techniques.
Promulgated guidelines should include what specific genetic tests should be designated
as the “standard of care” and under what circumstances.145 For instance, the American Society of
Clinical Oncology has already promulgated guidelines recognizing that cancer specialists may
not currently be fully informed of the range of issues that are involved in genetic testing for
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cancer risk.146 Medical professionals, especially those who work in genetic specialties, need to
publish similar established standards of care.147 The development of practice guidelines and
protocols for testing will help physicians by providing a reference for the changing standard of
care and serve as strategies for patient management and clinical decision making.
In addition to helping physicians with decision making in patient care management,
courts may benefit from having these practice guidelines in malpractice litigation as a reference
to the current standard of care. The U.S. tort system may allow compliance or noncompliance
with these guidelines to support malpractice claims or defenses. This will help promote
efficiency and uniformity and reduce wasteful litigation that may deter physicians from
incorporating genetic counseling and testing into their practices. These guidelines may also be
used for patient education and could possibly lower the risk of physician liability by resolving
ambiguity as to the governing standard. Genetic malpractice actions may force physicians either
to overuse genetic diagnostic testing to defend against genetic malpractice suits or to avoid
genetic services altogether by making blanket referrals.148 Without such policies and guidelines
physicians may fear litigation and may not be able act responsibly, leaving courts with the
burden of determining when a duty exists.
While new medical practice guidelines may increase physician sophistication and
improve the quality of American health care, their promulgation will likely be met with some
resistance from the medical community. Established guidelines will also not guarantee consistent
results from courts. Compliance with medical practice guidelines does not assure that a court will
find that a physician is not liable for malpractice. Rather,“[o]nce admitted into evidence, a
practice guideline does not constitute a predetermined standard of care that a court is obligated to
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apply.”149 From there, the court may consider other evidence regarding what the standard should
be, and it may stray from the practice guidelines if it finds that other evidence about the standard
is more persuasive.150 Although medical practice guidelines may not definitely establish the
standard of care, they will become a necessary resource for courts to work from and a valuable
reference particularly if it is periodically updated to include significant new advancements.
3. Incorporation of Electronic Health Records
Finally, providers may also adopt and improve genetic testing practices by incorporating
a system of “interoperable, clinically useful genetic laboratory test data and analytical tools into
electronic health records to support clinical decisionmaking for the health care provider and the
patient.151 Electronic health records may support maximal benefits from genetic tests by tracking
family history and provide an efficient means of delivering genetic test results. Although the
Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers to
discriminate on the basis of genetic information, patients may still have privacy concerns about
the incorporation of their genetic information in electronic health records. Thus, physicians
should encourage their patients to undergo testing by fully explaining existing privacy
protections and available remedies.
CONCLUSION
Whole genome sequencing and findings from ENCODE will make genetic testing more
accurate and powerfully predictive. Increasing availability and enforced privacy protections will
likely encourage more patients to undergo genetic testing. The ability to target and prevent
diseases through personalized medicine will prove to be an invaluable tool that will benefit
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physicians, patients, and the health care of the nation. Physicians liability for medical
malpractice provides justice for harmed patients and may promote the advancement and
proliferation of genetic testing. On the other hand, physician fear of frivolous lawsuits and the
burden of acquiring a vast and unfamiliar body of knowledge may discourage physicians from
engaging in these valuable new practices. In order to facilitate the growth of genetic testing
capabilities, courts should provide relief to a plaintiff only when the physician failed to utilize
appropriate care and demonstrated negligence.
In order to meet evolving standards of care, it is important for physicians who conduct
genetic tests to obtain the necessary skills and training in pretest and posttest education.152
Clinicians who meet these qualifications must thoroughly discuss with patients the degree to
which particular genetic risk factors correlate with the chance of developing the disease.153
Further, physicians should clearly present the risks and benefits of available testing and inform
patients of available genetic tests, including whole genome sequencing.154 If physicians are
unsure or unqualified of the services they are offering, they should be responsible for referring
their patients for further discussion.155 Clinicians should also be careful not to undertake testing
until all the potential consequences of learning genetic information are thoroughly disclosed to
the patient.156 In this context, it will be important to discuss potential effects of the patient’s wellbeing and that of family members; and the possibility of adverse use by employers, insurers, or
other institutions.157 Finally, if the patient’s genetic information reveals a condition that may not
be treated or prevented, physicians should be given the right to refrain from revealing the
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information to individuals other than the patient. Under all circumstances, it will be essential that
physicians receive appropriate training and education in genetics, and that patients who undergo
testing receive comprehensive genetic counseling.
As physicians are positioned at the forefront of this new realm, they are the most
qualified to establish the standard of care in genetic medicine. Thus, it will become imperative
for physicians to establish professional guidelines that help courts to set the standard of care and
serve as a reference in medical malpractices cases. Setting a baseline for the standard of care will
foster the adoption of genetic medicine among physicians and allow courts to apply a uniform
standard in medical malpractice cases. Once these standards of care have been established, the
medical community must continue to establish and abide by these standards and remain abreast
of current developments in genetics. With both the medical and legal communities better
prepared for the obstacles that will accompany newly emerging genetic technologies, the genetic
revolution can continue to make unprecedented breakthroughs in personalized care.
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